Pharmidex attending the Global Business Accelerator visit to Switzerland
March 10, 2018

Pharmidex will be attending the Global Business Accelerator Program which is run by the Enterprise Europe Network and supported by Innovate UK.

The Enterprise Europe Network, supported by Innovate UK, are visiting Switzerland to focus on the pharmaceutical technology industry. The chosen companies will have the opportunity to meet pharmaceutical companies and key stakeholders based in Basel and attend ProcureCon Pharma in Zürich for the next three days


The Swiss pharmaceutical sector is a major employer with more than 40,000 people working directly for the industry. If the indirect work created through ancillary industries is included, as many as 172,000 jobs are related to the pharmaceutical industry. In addition, it accounts for up to a third of all Swiss exports, and the productivity of the industry is four times as high as that of the economy as a whole.


Three big clusters – the Lake Geneva area, the Basel region and Zürich-Zug-Lucerne – account for the lion’s share of the gross value added of the Swiss pharmaceutical industry and present many collabartive opputunities for UK companies. 


During the trip Pharmidex will also be attending ProcureCon Pharma, organised by Worldwide Business Research, will take place from 13 to 15 March 2018 in Zürich. Delegates will have the opportunity to join 200 senior procurement professionals from Merck, Astra Zeneca, Roche, Sanofi, Lonza and other world-leading pharmaceutical businesses over three days. 


We look forward to meeting you there.

Pharmidex Drug Metabolism Services

March 4, 2026
🔬 Unlock deeper insights into how your compound is processed in the body with Pharmidex ’s Drug Metabolism Services. At Pharmidex , we provide specialist drug metabolism studies using advanced UHPLC-high resolution/accurate mass spectrometry to support biotransformation understanding, cross-species metabolite profiling and structural characterisation of metabolites. Our expert team can help you address challenges such as high clearance, identification of metabolically labile sites and potential reactive metabolism liabilities, helping you make data-driven decisions early in the discovery and development process. Learn how our tailored approach can strengthen your metabolic profiling and accelerate your drug development programmes: 🔗 https://www.pharmidex.com/Drug-Metabolism-Service

Pharmidex Discovery Bioanalysis

February 26, 2026
At Pharmidex , we deliver industry-leading Discovery Bioanalysis services grounded in advanced LC-MS technologies to enhance drug discovery and preclinical research, supporting internal studies but also analyzing external samples also Our experienced bioanalytical team works across a wide range of therapeutic modalities, from small molecules and peptides, to oligonucleotides and complex biologics, providing robust, reliable and fit-for-purpose data to accelerate your program and strengthen decision-making during early development. We support both non-GLP and GLP/GCP workflows, method development, validation, and quantitative analysis that align with regulatory needs and industry expectations. Learn more about how our LC-MS capabilities can help you confidently advance your projects: 🔗 https://www.pharmidex.com/Discovery-Bioanalysis

🍩 Donut Day at Pharmidex!

February 24, 2026
Today we took a short pause from the science to enjoy some well-deserved donuts together in the office. At Pharmidex , we believe culture matters just as much as capability. Moments like this simple, informal, and inclusive are part of what keeps our team connected and motivated. As a preclinical CRO, we support over 400 clients each year from our UK laboratories, delivering high-quality in vivo and bioanalytical services to advance drug discovery programmes.  A small break. A strong team. Back to delivering great science. If we can support your next drug discovery project, do get in touch.
More Posts